CYTO

Altamira Therapeutics Ltd. [CYTO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CYTO Stock Summary

In the News

CYTO Financial details

Company Rating
-
Market Cap
2.89M
Income
-336.32K
Revenue
1.59M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
10 Apr 2024
P/E
-0.09
Forward P/E
-
PEG
0.02
P/S
12.26
P/B
-0.29
P/C
-
P/FCF
-0.35
Quick Ratio
0.06
Current Ratio
0.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-11.4
EPS next Y
-
EPS next Q
-
EPS this Y
10.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-36.81%
Revenue last 5Y
-24.74%
Revenue Q/Q
-91.07%
EPS Q/Q
-85.77%
-
-
-
-
SMA20
-25%
SMA50
-72.09%
SMA100
-85.54%
Inst Own
-
Inst Trans
-
ROA
-421%
ROE
-1209%
ROC
3.97%
Gross Margin
-372%
Oper. Margin
-8551%
Profit Margin
-8680%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.61-29.0
52W High
-99.54%
52W Low
-86.71%
RSI
46.39
Rel Volume
-
Avg Volume
1.21M
Volume
1.76K
Perf Week
20.86%
Perf Month
66.19%
Perf Quarter
-
Perf Half Y
-86.55%
-
-
-
-
Beta
2.536
-
-
Volatility
0.01%, 0.03%
Prev Close
12.43%
Price
0.13295
Change
23.9%

Something similar

Top by Market Cap
ABEC.DE
BRK-B
TL0.DE
NVD.DE
FB2A.DE
Same Sector
NURO
1846.HK
000513.SZ
0VGI.L
E8X.DE
Same Price Range
CYTO
0554.HK
1617.HK
ADVBOX.ST
0432.HK
Similar Market Cap
RDT.L
RSLS
PDV.TO
ALQGC.PA
FNTC

Company Profile

Healthcare Biotechnology
  • Volume Average 1.21M
  • Market Capitalization 2.89M
  • Employee 16
  • CEO Dr. Covadonga Paneda
  • Headquarters Hamilton,BM
  • IPO Date 2014-08-06
  • Website https://altamiratherapeutics.com

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.